Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study.

Wolff SN, Marion J, Stein RS, Flexner JM, Lazarus HM, Spitzer TR, Phillips GL, Herzig RH, Herzig GP. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study. Blood. 1985 Jun; 65(6):1407-11.

View in: PubMed

© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.